You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
濟民製藥(603222.SH)擬向博鰲國際醫院增資1020萬元
格隆匯 02-04 19:17

格隆匯 2 月 4日丨濟民製藥(603222.SH)公佈,公司擬對控股子公司海南濟民博鰲國際醫院有限公司(“博鰲國際醫院”)進行現金增資,公司持有其51%的股權,公司需出資人民幣1020萬元。增資完成後,博鰲國際醫院註冊資本將由目前的2億元增加到2.2億元。

博鰲國際醫院是第一批進入海南博鰲樂城國際醫療旅遊先行區的企業和醫院,醫院總用地面積約81.2畝,總建築面積6.5萬平方米,核定病牀數560張。

醫院自2016年開始施工建設,工程及設備累計投入近5億元。醫院國際再生醫學中心於2018年5月開始對外營業,經過兩年多的發展,國際再生醫學研究中心、腫瘤精準防治中心、醫療級抗衰老醫學中心、高端體檢中心、女性醫學和醫學美容中心陸續完成建設並對外營業。2020年上半年,主要受疫情影響,醫院客流相對較少,下半年,隨着疫情的好轉,醫院收入成逐月遞增態勢,其中第四季度實現收入3780萬元,醫院經營逐步向好。

截至2020年12月31日,醫院銀行貸款餘額合計2.834億元,醫院資產負債率相對偏高,此次增資有利於醫院降低資產負債率,提升醫院經營流動性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account